These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33818020)

  • 1. MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
    Feng Q; Ren Y; Hou A; Guo J; Mao Z; Liu S; Wang B; Bai Z; Hou X
    J Breast Cancer; 2021 Apr; 24(2):153-163. PubMed ID: 33818020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
    Qin X; Chang F; Wang Z; Jiang W
    Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Let-7f and miRNA-126 correlate with reduced cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy.
    Zhu Z; Li X; Dong H; Ke S; Zheng WH
    Int J Clin Exp Pathol; 2018; 11(10):4987-4995. PubMed ID: 31949575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.
    Tan L; Su X; Li X; Li H; Hu B
    Int J Clin Exp Pathol; 2020; 13(2):286-294. PubMed ID: 32211111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
    Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
    Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients.
    Liu H; Hu X; Wang L; Du T; Feng J; Li M; Liu L; Liu X
    Front Surg; 2022; 9():862617. PubMed ID: 35647022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy.
    Katsurada K; Ichida M; Sakuragi M; Takehara M; Hozumi Y; Kario K
    Springerplus; 2014; 3():620. PubMed ID: 25392790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
    Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
    Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.